» Articles » PMID: 30663254

PROMIS Pediatric Measures Validated in a Longitudinal Study Design in Pediatric Oncology

Overview
Date 2019 Jan 22
PMID 30663254
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study assessed the responsiveness to change over time and theorized associations of Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures in children and adolescents in treatment for cancer to determine measure readiness for use in cancer clinical trials.

Methods: We administered eight PROMIS (three symptom, two psychological, and three performance) pediatric short-form measures and the Symptom Distress Scale (SDS) to 96 pediatric oncology patients at three time points during a course of chemotherapy. We assessed responsiveness using paired t tests and generalized estimating equation (GEE) models, calculated standardized response mean (SRM) values for PROMIS measures, and examined scores over three data points (T1-T3). Guided by the theory of unpleasant symptoms (TOUS), we examined associations among the PROMIS measures, the SDS, and other variables using GEE.

Results: The paired t tests showed statistically significant changes in two psychological measures and one performance measure from T1 to T2; three symptom, two psychological and two performance measures from T2 to T3; and three symptom and two psychological measures from T1 to T3. Findings from GEE models indicate PROMIS pediatric measures had statistically significant short-term and long-term changes, controlling for demographic and clinical variables. One performance measure did not achieve significant change at any time point. We found positive support for theorized relationships in the TOUS.

Conclusions: Most of the PROMIS pediatric measures demonstrated changes over time and had significant relationships as theorized, thus supporting concurrent and construct validity of these measures when administered to pediatric oncology patients during a course of chemotherapy. This evidence supports the measures' readiness for use in clinical trials.

Citing Articles

Co-Design and Evaluation Protocol for the RECOVER Model of Care After Childhood Cancer Treatment.

Bradford N, Cashion C, Sharwood E, Rumble S, Condon P, Cossio D Healthcare (Basel). 2025; 13(5).

PMID: 40077016 PMC: 11899481. DOI: 10.3390/healthcare13050454.


Patient-Reported Outcomes Measurement Information System as a Clinical Tool for Capturing the Patient Perspective in Pediatric Inflammatory Bowel Disease: A Narrative Review.

Azevedo S, Lopes A Children (Basel). 2025; 11(12.

PMID: 39767921 PMC: 11674067. DOI: 10.3390/children11121492.


Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.

Mueller S, Fangusaro J, Thomas A, Jacques T, Bandopadhayay P, de Blank P Neuro Oncol. 2023; 26(3):407-416.

PMID: 38146999 PMC: 10912006. DOI: 10.1093/neuonc/noad227.


Delivering a Home-Based Exercise Program to Youth With Osteogenesis Imperfecta: Protocol for a Comparative-Approach Study.

Powell G, Gagnon M, Komarova S, Rauch F, Veilleux L JMIR Res Protoc. 2023; 12:e40262.

PMID: 37399052 PMC: 10365614. DOI: 10.2196/40262.


A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

van Kalsbeek R, Hudson M, Mulder R, Ehrhardt M, Green D, Mulrooney D Nat Med. 2023; 29(6):1340-1348.

PMID: 37322119 DOI: 10.1038/s41591-023-02339-y.